Executive Summary of the 2025 Global Medtech Contract Development and Manufacturing Report.

The medtech contract development and manufacturing organization (CDMO) market plays a critical role in the evolving healthcare landscape. As medical devices grow more complex and regulatory demands intensify, original equipment manufacturers (OEMs) are increasingly outsourcing to CDMOs not just for production, but for integrated, end-to-end innovation support. For industry leaders and investors, staying up to date on this market is essential to navigate risk, identify growth opportunities, and maintain a competitive edge.

In recent years, the CDMO sector has undergone a major shift, from transactional manufacturing to strategic partnership models. These organizations now sit at the core of device innovation, supply chain resilience, and market scalability.

This article consolidates key developments from 2024 and outlines what to expect in 2025, including market growth dynamics, M&A activity, and investment priorities.

For an in-depth analysis of the global CDMO medtech market, download our 2025 Global Medtech Contract Development and Manufacturing Report.

2024 Overview: A Year of Momentum and Strategic Shifts

In 2024, the global medtech outsourcing market reached $89 billion, growing 9.2% over the previous year. Growth was driven by OEMs increasingly outsourcing not only production but also design and development, aiming to de-risk operations and accelerate product timelines. CDMOs proved indispensable as strategic partners amid heightened regulatory complexity and increased demand for device customization.

Market shifts in 2024 reflected broader structural changes:

• Reorganization among OEMs led to increased reliance on external partners.
• Material innovation—such as nitinol and next-gen plastics—enabled CDMOs to support more advanced, differentiated products.
• End-market expansion, especially in cardiology and drug delivery, increased demand for specialized manufacturing.
• Sustainability considerations began influencing production decisions and vendor selection.

Private equity played a central role in market consolidation. With 64 global CDMO-related deals and 93 PE-backed platforms tracked, 2024 was a high-activity year for M&A. Investors showed growing confidence in CDMO platforms, particularly those offering niche capabilities and proven growth trajectories.

2025 Outlook: Slower Growth Sharper Focus

Despite a strong 2024, growth in 2025 is expected to moderate to single digits. Several headwinds are contributing to this more cautious forecast:

• Tariff volatility, supply chain recalibration, and geopolitical risk are creating planning uncertainty.
• Pricing pressure and OEM cost containment strategies are squeezing margins.
• Innovation funding is tightening, and post-COVID inventory corrections are still unfolding.

Still, 2025 presents a meaningful opportunity for well-positioned CDMOs. The shift toward personalized medicine and patient-specific devices is creating demand for advanced, flexible manufacturing solutions. CDMOs are expected to continue investing in automation, digital manufacturing, and customization at a scale to meet these needs while maintaining cost-efficiency and compliance.

M&A activity is forecast to remain strong, with particular interest in CDMOs specializing in:

• Drug-device combination products
• Active implantables
• Complex electromechanical systems

These specialized capabilities are driving competition among acquirers and pushing valuations higher. Strategic exits and secondary buyouts are both on the table, though timing will depend on macroeconomic conditions and regulatory developments. Differentiation and scalability will be critical for platforms aiming to attract buyers or investors in 2025.

Conclusion

The medtech CDMO market continues to be a high-stakes, high-potential segment of the healthcare industry. 2024 confirmed its strategic importance, while 2025 introduces a more complex landscape that demands focus, adaptability, and investment in innovation.

For CDMOs, OEMs, and investors alike, the ability to anticipate and respond to shifting dynamics—technological, regulatory, and economic—will define who leads and who lags in the next chapter of medtech outsourcing.